Pfizer introduces a new HER2-negative breast cancer targeted treatment

A targeted therapy for HER2-negative patients is expected to be introduced in the domestic market.

According to the industry concerned on the 7^th, Pfizer Pharmaceuticals Korea has recently turned in an approval application of ‘Ibrance(palbociclib),’ a breast cancer treatment. Considering the usual procedure, it is expected to acquire approval in the second half of the year.

Generally, the pro...